25 XP   0   0   10

Mesoblast Ltd
Buy, Hold or Sell?

Let's analyse Mesoblast together

PenkeI guess you are interested in Mesoblast Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mesoblast Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mesoblast Ltd

I send you an email if I find something interesting about Mesoblast Ltd.

Quick analysis of Mesoblast (30 sec.)










What can you expect buying and holding a share of Mesoblast? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.45
Expected worth in 1 year
A$0.45
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
A$0.01
Return On Investment
0.8%

For what price can you sell your share?

Current Price per Share
A$0.93
Expected price per share
A$0.42666666666667 - A$0.975
How sure are you?
50%

1. Valuation of Mesoblast (5 min.)




Live pricePrice per Share (EOD)

A$0.93

Intrinsic Value Per Share

A$0.45 - A$0.57

Total Value Per Share

A$0.90 - A$1.01

2. Growth of Mesoblast (5 min.)




Is Mesoblast growing?

Current yearPrevious yearGrowGrow %
How rich?$332.4m$329.5m-$2.5m-0.8%

How much money is Mesoblast making?

Current yearPrevious yearGrowGrow %
Making money-$11.9m-$13.7m$1.8m15.4%
Net Profit Margin-976.2%-1,084.0%--

How much money comes from the company's main activities?

3. Financial Health of Mesoblast (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#165 / 1010

Most Revenue
#484 / 1010

Most Profit
#588 / 1010

Most Efficient
#808 / 1010

What can you expect buying and holding a share of Mesoblast? (5 min.)

Welcome investor! Mesoblast's management wants to use your money to grow the business. In return you get a share of Mesoblast.

What can you expect buying and holding a share of Mesoblast?

First you should know what it really means to hold a share of Mesoblast. And how you can make/lose money.

Speculation

The Price per Share of Mesoblast is A$0.93. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mesoblast.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mesoblast, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.45. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mesoblast.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-1.0%-0.01-1.1%-0.01-1.3%-0.01-1.3%-0.01-1.1%
Usd Book Value Change Per Share0.000.0%0.000.1%-0.01-0.5%0.000.0%0.00-0.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.1%-0.01-0.5%0.000.0%0.00-0.2%
Usd Price Per Share0.20-0.45-0.56-1.06-1.36-
Price to Earnings Ratio-5.43--10.38--11.69--24.21--24.00-
Price-to-Total Gains Ratio23.30--14.31--78.61-7.17-
Price to Book Ratio0.70-1.60-1.93-3.54-4.44-
Price-to-Total Gains Ratio23.30--14.31--78.61-7.17-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.607755
Number of shares1645
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (1645 shares)2.06-0.75
Gains per Year (1645 shares)8.23-2.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108-20-3-13
201660-6-16
3025140-9-19
4033220-12-22
5041300-15-25
6049380-18-28
7058460-21-31
8066540-24-34
9074620-27-37
10082700-30-40

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.035.03.05.0%4.035.033.05.6%
Book Value Change Per Share2.01.01.050.0%4.06.02.033.3%6.012.02.030.0%14.022.04.035.0%23.032.017.031.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.072.00.0%
Total Gains per Share2.01.01.050.0%4.06.02.033.3%6.012.02.030.0%14.022.04.035.0%23.032.017.031.9%

Fundamentals of Mesoblast

About Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-04-26 06:40:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Mesoblast Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mesoblast earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Net Profit Margin of -960.4% means that $-9.60 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mesoblast Ltd:

  • The MRQ is -960.4%. The company is making a huge loss. -2
  • The TTM is -976.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-960.4%TTM-976.2%+15.8%
TTM-976.2%YOY-1,084.0%+107.8%
TTM-976.2%5Y-1,222.7%+246.5%
5Y-1,222.7%10Y-1,174.0%-48.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-960.4%-207.2%-753.2%
TTM-976.2%-216.8%-759.4%
YOY-1,084.0%-282.3%-801.7%
5Y-1,222.7%-436.8%-785.9%
10Y-1,174.0%-597.3%-576.7%
1.1.2. Return on Assets

Shows how efficient Mesoblast is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • -2.4% Return on Assets means that Mesoblast generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mesoblast Ltd:

  • The MRQ is -2.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-2.7%+0.3%
TTM-2.7%YOY-3.2%+0.4%
TTM-2.7%5Y-3.1%+0.4%
5Y-3.1%10Y-2.4%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.4%-13.3%+10.9%
TTM-2.7%-12.8%+10.1%
YOY-3.2%-11.6%+8.4%
5Y-3.1%-13.8%+10.7%
10Y-2.4%-15.6%+13.2%
1.1.3. Return on Equity

Shows how efficient Mesoblast is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • -3.2% Return on Equity means Mesoblast generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mesoblast Ltd:

  • The MRQ is -3.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.2%TTM-3.7%+0.5%
TTM-3.7%YOY-4.2%+0.5%
TTM-3.7%5Y-4.1%+0.5%
5Y-4.1%10Y-3.3%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.2%-16.9%+13.7%
TTM-3.7%-16.1%+12.4%
YOY-4.2%-14.9%+10.7%
5Y-4.1%-19.3%+15.2%
10Y-3.3%-20.1%+16.8%

1.2. Operating Efficiency of Mesoblast Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mesoblast is operating .

  • Measures how much profit Mesoblast makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • An Operating Margin of -784.7% means the company generated $-7.85  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mesoblast Ltd:

  • The MRQ is -784.7%. The company is operating very inefficient. -2
  • The TTM is -796.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-784.7%TTM-796.0%+11.4%
TTM-796.0%YOY-987.6%+191.5%
TTM-796.0%5Y-1,108.4%+312.4%
5Y-1,108.4%10Y-1,173.1%+64.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-784.7%-298.0%-486.7%
TTM-796.0%-238.5%-557.5%
YOY-987.6%-288.4%-699.2%
5Y-1,108.4%-486.2%-622.2%
10Y-1,173.1%-628.4%-544.7%
1.2.2. Operating Ratio

Measures how efficient Mesoblast is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.62 means that the operating costs are $7.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mesoblast Ltd:

  • The MRQ is 7.624. The company is inefficient in keeping operating costs low. -1
  • The TTM is 11.885. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.624TTM11.885-4.262
TTM11.885YOY16.434-4.548
TTM11.8855Y16.575-4.690
5Y16.57510Y15.991+0.584
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6243.235+4.389
TTM11.8853.310+8.575
YOY16.4343.838+12.596
5Y16.5755.679+10.896
10Y15.9917.823+8.168

1.3. Liquidity of Mesoblast Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mesoblast is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.71 means the company has $2.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mesoblast Ltd:

  • The MRQ is 2.715. The company is able to pay all its short-term debts. +1
  • The TTM is 2.128. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.715TTM2.128+0.587
TTM2.128YOY1.514+0.614
TTM2.1285Y1.562+0.566
5Y1.56210Y2.018-0.456
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7153.863-1.148
TTM2.1284.169-2.041
YOY1.5145.337-3.823
5Y1.5626.122-4.560
10Y2.0186.434-4.416
1.3.2. Quick Ratio

Measures if Mesoblast is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Quick Ratio of 2.53 means the company can pay off $2.53 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mesoblast Ltd:

  • The MRQ is 2.530. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.988. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.530TTM1.988+0.542
TTM1.988YOY1.410+0.578
TTM1.9885Y1.445+0.543
5Y1.44510Y1.848-0.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5303.504-0.974
TTM1.9883.991-2.003
YOY1.4105.371-3.961
5Y1.4456.088-4.643
10Y1.8486.395-4.547

1.4. Solvency of Mesoblast Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mesoblast assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mesoblast to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Mesoblast assets are financed with 24.1% credit (debt) and the remaining percentage (100% - 24.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mesoblast Ltd:

  • The MRQ is 0.241. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.248. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.241TTM0.248-0.007
TTM0.248YOY0.247+0.001
TTM0.2485Y0.248+0.000
5Y0.24810Y0.267-0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2410.339-0.098
TTM0.2480.337-0.089
YOY0.2470.271-0.024
5Y0.2480.368-0.120
10Y0.2670.388-0.121
1.4.2. Debt to Equity Ratio

Measures if Mesoblast is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.8% means that company has $0.32 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mesoblast Ltd:

  • The MRQ is 0.318. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.330. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.318TTM0.330-0.012
TTM0.330YOY0.327+0.002
TTM0.3305Y0.3300.000
5Y0.33010Y0.380-0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3180.392-0.074
TTM0.3300.403-0.073
YOY0.3270.335-0.008
5Y0.3300.427-0.097
10Y0.3800.461-0.081

2. Market Valuation of Mesoblast Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mesoblast generates.

  • Above 15 is considered overpriced but always compare Mesoblast to the Biotechnology industry mean.
  • A PE ratio of -5.43 means the investor is paying $-5.43 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mesoblast Ltd:

  • The EOD is -16.301. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.434. Based on the earnings, the company is expensive. -2
  • The TTM is -10.381. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.301MRQ-5.434-10.868
MRQ-5.434TTM-10.381+4.947
TTM-10.381YOY-11.686+1.305
TTM-10.3815Y-24.213+13.831
5Y-24.21310Y-23.999-0.213
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.301-2.300-14.001
MRQ-5.434-2.656-2.778
TTM-10.381-2.718-7.663
YOY-11.686-4.145-7.541
5Y-24.213-6.258-17.955
10Y-23.999-6.315-17.684
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mesoblast Ltd:

  • The EOD is -19.817. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.606. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.674. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.817MRQ-6.606-13.212
MRQ-6.606TTM-12.674+6.068
TTM-12.674YOY-16.575+3.901
TTM-12.6745Y-35.865+23.191
5Y-35.86510Y-23.520-12.345
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.817-2.974-16.843
MRQ-6.606-3.306-3.300
TTM-12.674-3.508-9.166
YOY-16.575-5.613-10.962
5Y-35.865-8.378-27.487
10Y-23.520-8.873-14.647
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mesoblast is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.70 means the investor is paying $0.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mesoblast Ltd:

  • The EOD is 2.085. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.695. Based on the equity, the company is cheap. +2
  • The TTM is 1.596. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.085MRQ0.695+1.390
MRQ0.695TTM1.596-0.901
TTM1.596YOY1.929-0.332
TTM1.5965Y3.543-1.947
5Y3.54310Y4.445-0.901
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0851.914+0.171
MRQ0.6952.116-1.421
TTM1.5962.097-0.501
YOY1.9292.881-0.952
5Y3.5433.550-0.007
10Y4.4453.936+0.509
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mesoblast Ltd.

3.1. Funds holding Mesoblast Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-10-31Vanguard International Stock Index-Total Intl Stock Indx1.13-7333452--
2020-12-31Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.49-3162015--
2021-02-28iShares Core MSCI EAFE ETF0.34-2192913--
2021-02-28iShares MSCI EAFE Small Cap ETF0.33000002-2139899--
2021-01-31DFA Asia Pacific Small Company Series0.23999999-1561474--
2020-10-31Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index0.2-1284383--
2021-02-28iShares Core MSCI Total International Stock ETF0.11-742482--
2020-11-30Schwab Strategic Tr-Schwab International Small Cap Equity ETF0.11-701021--
2020-12-31College Retirement Equities Fund-Stock Account0.07-473074--
2021-01-31Vanguard International Stock Index-Pacific Stock Index0.07-457924--
Total 3.0900000102004863700.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mesoblast Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-100%-0.0080%-0.0010%-0.0030%
Book Value Per Share--0.4460.439+2%0.442+1%0.454-2%0.462-4%
Current Ratio--2.7152.128+28%1.514+79%1.562+74%2.018+35%
Debt To Asset Ratio--0.2410.248-3%0.247-2%0.248-3%0.267-10%
Debt To Equity Ratio--0.3180.330-4%0.327-3%0.330-4%0.380-16%
Dividend Per Share----0%-0%-0%-0%
Eps---0.014-0.016+12%-0.018+29%-0.019+32%-0.015+6%
Free Cash Flow Per Share---0.012-0.013+13%-0.013+10%-0.013+14%-0.016+35%
Free Cash Flow To Equity Per Share--0.002-0.003+220%-0.005+359%0.001+43%0.000+104%
Gross Profit Margin--1.0001.183-16%1.410-29%1.119-11%0.984+2%
Intrinsic Value_10Y_max--0.566--------
Intrinsic Value_10Y_min--0.454--------
Intrinsic Value_1Y_max---0.028--------
Intrinsic Value_1Y_min---0.028--------
Intrinsic Value_3Y_max---0.020--------
Intrinsic Value_3Y_min---0.021--------
Intrinsic Value_5Y_max--0.066--------
Intrinsic Value_5Y_min--0.056--------
Market Cap1060860314.880+67%353620104.960792764943.370-55%971029401.120-64%1854783078.916-81%2373672102.769-85%
Net Profit Margin---9.604-9.762+2%-10.840+13%-12.227+27%-11.740+22%
Operating Margin---7.847-7.960+1%-9.876+26%-11.084+41%-11.731+50%
Operating Ratio--7.62411.885-36%16.434-54%16.575-54%15.991-52%
Pb Ratio2.085+67%0.6951.596-56%1.929-64%3.543-80%4.445-84%
Pe Ratio-16.301-200%-5.434-10.381+91%-11.686+115%-24.213+346%-23.999+342%
Price Per Share0.930+67%0.3100.695-55%0.851-64%1.626-81%2.081-85%
Price To Free Cash Flow Ratio-19.817-200%-6.606-12.674+92%-16.575+151%-35.865+443%-23.520+256%
Quick Ratio--2.5301.988+27%1.410+79%1.445+75%1.848+37%
Return On Assets---0.024-0.027+13%-0.032+30%-0.031+28%-0.024-2%
Return On Equity---0.032-0.037+14%-0.042+31%-0.041+29%-0.033+3%
Total Gains Per Share---0.002-100%-0.0080%-0.0010%-0.0030%
Usd Book Value--332455708.500326989834.500+2%329510547.375+1%338129656.900-2%344771281.960-4%
Usd Book Value Change Per Share---0.001-100%-0.0050%0.0000%-0.0020%
Usd Book Value Per Share--0.2910.287+2%0.289+1%0.296-2%0.302-4%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.009-0.010+12%-0.012+29%-0.012+32%-0.010+6%
Usd Free Cash Flow---8745790.500-9870627.375+13%-9616252.500+10%-9983486.825+14%-10603609.313+21%
Usd Free Cash Flow Per Share---0.008-0.009+13%-0.008+10%-0.009+14%-0.010+35%
Usd Free Cash Flow To Equity Per Share--0.001-0.002+220%-0.004+359%0.001+43%0.000+104%
Usd Market Cap693272215.774+67%231090738.591518071890.492-55%634567713.632-64%1212100742.072-81%1551194719.160-85%
Usd Price Per Share0.608+67%0.2030.454-55%0.556-64%1.063-81%1.360-85%
Usd Profit---10632118.250-11935850.750+12%-13769245.000+30%-13997185.800+32%-11314290.563+6%
Usd Revenue--1107029.0001219757.750-9%1285924.625-14%2095807.175-47%2952709.050-63%
Usd Total Gains Per Share---0.001-100%-0.0050%0.0000%-0.0020%
 EOD+5 -2MRQTTM+22 -11YOY+22 -75Y+19 -1010Y+19 -10

4.2. Fundamental Score

Let's check the fundamental score of Mesoblast Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.301
Price to Book Ratio (EOD)Between0-12.085
Net Profit Margin (MRQ)Greater than0-9.604
Operating Margin (MRQ)Greater than0-7.847
Quick Ratio (MRQ)Greater than12.530
Current Ratio (MRQ)Greater than12.715
Debt to Asset Ratio (MRQ)Less than10.241
Debt to Equity Ratio (MRQ)Less than10.318
Return on Equity (MRQ)Greater than0.15-0.032
Return on Assets (MRQ)Greater than0.05-0.024
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Mesoblast Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.925
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets670,285
Total Liabilities161,554
Total Stockholder Equity508,731
 As reported
Total Liabilities 161,554
Total Stockholder Equity+ 508,731
Total Assets = 670,285

Assets

Total Assets670,285
Total Current Assets85,154
Long-term Assets585,131
Total Current Assets
Cash And Cash Equivalents 77,554
Net Receivables 1,804
Inventory 0
Other Current Assets 5,796
Total Current Assets  (as reported)85,154
Total Current Assets  (calculated)85,154
+/-0
Long-term Assets
Property Plant Equipment 5,500
Goodwill 134,453
Intangible Assets 442,111
Long-term Assets Other 2,241
Long-term Assets  (as reported)585,131
Long-term Assets  (calculated)584,305
+/- 826

Liabilities & Shareholders' Equity

Total Current Liabilities31,367
Long-term Liabilities130,187
Total Stockholder Equity508,731
Total Current Liabilities
Short-term Debt 8,534
Accounts payable 10,760
Other Current Liabilities 12,073
Total Current Liabilities  (as reported)31,367
Total Current Liabilities  (calculated)31,367
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)130,187
Long-term Liabilities  (calculated)0
+/- 130,187
Total Stockholder Equity
Common Stock1,286,229
Retained Earnings -853,344
Accumulated Other Comprehensive Income 75,846
Total Stockholder Equity (as reported)508,731
Total Stockholder Equity (calculated)508,731
+/-0
Other
Cash and Short Term Investments 77,554
Common Stock Shares Outstanding 851,464
Liabilities and Stockholders Equity 670,285
Net Debt 41,594
Short Long Term Debt Total 119,148



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302004-12-31
> Total Assets 
24,132
21,354
18,238
18,238
16,447
16,385
25,639
25,639
21,238
21,238
31,168
31,168
27,789
27,789
20,317
20,317
26,975
26,975
24,588
24,588
39,515
39,515
656,380
656,380
763,251
763,251
744,036
744,036
720,456
720,456
680,413
680,413
883,712
883,712
0
1,001,089
899,314
899,314
816,853
964,580
0
1,017,925
752,867
790,953
770,142
684,018
665,444
660,880
679,160
655,686
671,898
664,811
677,859
692,443
688,789
688,333
675,705
652,115
653,786
690,237
665,790
733,602
712,572
687,310
766,125
744,717
721,819
704,439
662,142
662,142
684,496
668,060
650,441
669,415
670,285
670,285
670,285670,285669,415650,441668,060684,496662,142662,142704,439721,819744,717766,125687,310712,572733,602665,790690,237653,786652,115675,705688,333688,789692,443677,859664,811671,898655,686679,160660,880665,444684,018770,142790,953752,8671,017,9250964,580816,853899,314899,3141,001,0890883,712883,712680,413680,413720,456720,456744,036744,036763,251763,251656,380656,38039,51539,51524,58824,58826,97526,97520,31720,31727,78927,78931,16831,16821,23821,23825,63925,63916,38516,44718,23818,23821,35424,132
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
217,736
0
186,383
0
331,844
0
271,540
0
203,749
0
163,199
0
159,453
0
132,519
112,130
88,823
70,697
67,001
86,472
63,609
80,327
72,272
86,069
101,071
97,811
97,801
85,527
62,522
60,593
93,307
69,393
136,548
115,737
90,458
169,766
148,227
126,220
108,797
69,837
69,837
92,960
78,133
61,365
81,658
85,154
85,154
85,15485,15481,65861,36578,13392,96069,83769,837108,797126,220148,227169,76690,458115,737136,54869,39393,30760,59362,52285,52797,80197,811101,07186,06972,27280,32763,60986,47267,00170,69788,823112,130132,5190159,4530163,1990203,7490271,5400331,8440186,3830217,73600000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
206,749
0
178,651
0
315,309
0
250,262
0
196,394
0
149,195
0
144,142
0
120,783
99,929
80,937
60,355
33,902
69,122
45,761
62,941
47,386
59,539
37,763
55,143
77,022
70,385
50,426
34,536
81,348
60,077
129,328
108,123
77,528
158,263
136,881
115,956
94,414
60,034
60,034
85,112
67,219
48,396
70,920
77,554
77,554
77,55477,55470,92048,39667,21985,11260,03460,03494,414115,956136,881158,26377,528108,123129,32860,07781,34834,53650,42670,38577,02255,14337,76359,53947,38662,94145,76169,12233,90260,35580,93799,929120,7830144,1420149,1950196,3940250,2620315,3090178,6510206,74900000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
191
0
0
0
000191000000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
297
201
746
746
151
88
1,097
1,097
510
510
325
325
124
124
650
650
305
305
316
316
1,376
1,376
455
455
2,101
2,101
4,634
4,634
10,669
10,669
7,409
7,409
12,063
12,063
0
16,855
6,098
6,098
9,010
9,191
0
5,172
8,371
7,833
8,108
4,054
4,583
27,133
6,522
3,493
4,340
11,986
11,824
50,116
29,288
3,683
3,508
3,810
17,607
2,841
2,751
1,322
2,446
3,090
2,695
4,590
5,627
6,048
4,403
4,403
3,863
4,221
7,182
6,998
1,804
1,804
1,8041,8046,9987,1824,2213,8634,4034,4036,0485,6274,5902,6953,0902,4461,3222,7512,84117,6073,8103,5083,68329,28850,11611,82411,9864,3403,4936,52227,1334,5834,0548,1087,8338,3715,17209,1919,0106,0986,09816,855012,06312,0637,4097,40910,66910,6694,6344,6342,1012,1014554551,3761,3763163163053056506501241243253255105101,0971,09788151746746201297
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,799
4,576
-4,324
0
0
00-4,3244,5765,79900000000000000000000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
502,719
0
494,031
0
551,868
0
729,549
0
695,565
0
801,381
0
858,472
0
658,434
658,012
595,195
594,747
593,879
592,688
592,077
591,571
592,539
591,790
591,372
590,978
590,532
590,178
589,593
593,193
596,930
596,397
597,054
596,835
596,852
596,359
596,490
595,599
595,642
592,305
592,305
591,536
589,927
589,076
587,757
585,131
585,131
585,131585,131587,757589,076589,927591,536592,305592,305595,642595,599596,490596,359596,852596,835597,054596,397596,930593,193589,593590,178590,532590,978591,372591,790592,539591,571592,077592,688593,879594,747595,195658,012658,4340858,4720801,3810695,5650729,5490551,8680494,0310502,71900000000000000000000000000000
       Property Plant Equipment 
0
28
24
24
38
38
57
57
158
158
193
193
198
198
222
222
246
246
238
238
224
224
247
247
610
610
842
842
1,998
1,998
2,651
2,651
2,757
2,757
0
3,150
4,683
4,683
4,456
5,532
0
5,727
3,990
3,742
3,439
3,063
2,925
2,485
2,153
1,814
1,636
1,453
1,263
1,084
1,016
871
825
826
5,211
9,596
9,444
10,271
10,332
10,413
10,236
12,140
11,235
11,503
9,965
9,965
9,516
8,154
7,125
6,491
5,500
5,500
5,5005,5006,4917,1258,1549,5169,9659,96511,50311,23512,14010,23610,41310,33210,2719,4449,5965,2118268258711,0161,0841,2631,4531,6361,8142,1532,4852,9253,0633,4393,7423,9905,72705,5324,4564,6834,6833,15002,7572,7572,6512,6511,9981,998842842610610247247224224238238246246222222198198193193158158575738382424280
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115,874
115,874
109,739
109,739
116,394
116,394
116,211
116,211
114,051
114,051
127,687
127,687
0
147,930
140,517
140,517
134,387
163,928
0
175,069
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453134,453175,0690163,928134,387140,517140,517147,9300127,687127,687114,051114,051116,211116,211116,394116,394109,739109,739115,874115,8740000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,997
1,997
1,911
1,997
2,018
2,065
2,138
2,321
2,408
2,516
2,601
2,317
1,952
1,672
1,766
1,871
1,952
1,899
1,981
2,080
2,234
2,347
2,032
1,758
1,843
1,949
2,032
1,757
0
0
001,7572,0321,9491,8431,7582,0322,3472,2342,0801,9811,8991,9521,8711,7661,6721,9522,3172,6012,5162,4082,3212,1382,0652,0181,9971,9111,9971,9970000000000000000000000000000000000000000000000
       Intangible Assets 
688
705
751
751
806
806
810
810
818
818
548
548
526
526
504
504
482
482
460
460
439
439
504,050
504,050
475,326
475,326
497,111
497,111
497,219
381,008
487,942
373,891
547,834
420,147
0
576,344
687,904
547,387
649,771
628,642
0
671,599
650,271
515,793
515,602
453,370
453,010
452,619
452,260
451,897
451,534
451,169
450,550
450,153
449,757
449,362
448,968
448,673
448,278
447,885
447,490
447,148
446,764
446,877
446,486
446,093
445,725
445,383
444,199
444,199
443,822
443,449
443,078
442,730
442,111
442,111
442,111442,111442,730443,078443,449443,822444,199444,199445,383445,725446,093446,486446,877446,764447,148447,490447,885448,278448,673448,968449,362449,757450,153450,550451,169451,534451,897452,260452,619453,010453,370515,602515,793650,271671,5990628,642649,771547,387687,904576,3440420,147547,834373,891487,942381,008497,219497,111497,111475,326475,326504,050504,050439439460460482482504504526526548548818818810810806806751751705688
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,277
0
2,125
0
2,978
0
3,279
0
3,082
0
2,331
2,366
2,343
2,362
2,325
1,911
1,916
1,930
3,399
3,386
3,361
3,344
3,330
3,331
3,324
3,299
3,324
3,244
3,311
3,334
3,210
3,203
1,724
1,952
1,956
1,930
1,930
1,902
1,922
2,388
481
2,241
2,241
2,2412,2414812,3881,9221,9021,9301,9301,9561,9521,7243,2033,2103,3343,3113,2443,3243,2993,3243,3313,3303,3443,3613,3863,3991,9301,9161,9112,3252,3622,3432,3662,33103,08203,27902,97802,12501,277000000000000000000000000000000000
> Total Liabilities 
3,824
2,203
1,708
1,708
4,482
4,420
729
729
699
699
1,716
1,716
1,573
1,573
1,543
1,543
1,185
1,185
1,496
1,496
1,596
1,596
240,043
240,043
247,406
247,406
248,010
248,010
241,608
241,608
226,891
226,891
253,446
253,446
0
363,333
327,596
327,596
304,328
379,706
0
408,566
300,041
298,199
291,207
155,857
155,572
150,363
138,759
138,920
112,308
89,206
121,724
146,435
161,190
163,776
174,763
171,063
178,639
189,433
177,977
184,276
174,066
168,579
165,195
163,320
162,073
168,930
165,098
165,098
161,689
168,058
168,273
167,577
161,554
161,554
161,554161,554167,577168,273168,058161,689165,098165,098168,930162,073163,320165,195168,579174,066184,276177,977189,433178,639171,063174,763163,776161,190146,435121,72489,206112,308138,920138,759150,363155,572155,857291,207298,199300,041408,5660379,706304,328327,596327,596363,3330253,446253,446226,891226,891241,608241,608248,010248,010247,406247,406240,043240,0431,5961,5961,4961,4961,1851,1851,5431,5431,5731,5731,7161,7166996997297294,4204,4821,7081,7082,2033,824
   > Total Current Liabilities 
3,824
2,203
1,708
1,708
4,482
4,420
729
729
699
699
1,716
1,716
1,573
1,573
1,543
1,543
1,185
1,185
1,496
1,496
1,581
1,581
29,258
29,258
30,795
30,795
36,496
36,496
44,495
44,494
33,909
33,909
50,588
50,588
0
59,603
42,675
42,675
37,931
53,464
0
63,031
40,400
41,679
41,261
29,415
31,321
29,099
29,661
36,670
22,770
21,591
24,861
24,003
27,393
33,809
44,502
44,331
70,092
76,957
76,689
90,143
87,697
91,040
98,546
94,273
92,899
57,954
51,373
51,373
48,802
54,576
53,917
41,982
31,367
31,367
31,36731,36741,98253,91754,57648,80251,37351,37357,95492,89994,27398,54691,04087,69790,14376,68976,95770,09244,33144,50233,80927,39324,00324,86121,59122,77036,67029,66129,09931,32129,41541,26141,67940,40063,031053,46437,93142,67542,67559,603050,58850,58833,90933,90944,49444,49536,49636,49630,79530,79529,25829,2581,5811,5811,4961,4961,1851,1851,5431,5431,5731,5731,7161,7166996997297294,4204,4821,7081,7082,2033,824
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,422
59,397
0
3,095
9,359
14,007
18,851
18,928
0
0
0
41,571
52,673
55,965
56,987
8,692
8,203
8,203
9,098
9,798
10,919
10,012
8,534
8,534
8,5348,53410,01210,9199,7989,0988,2038,2038,69256,98755,96552,67341,57100018,92818,85114,0079,3593,095059,39731,4220000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,422
59,397
0
3,095
9,359
14,007
18,851
18,928
27,000
32,455
34,893
41,571
52,673
53,200
53,847
5,203
5,523
5,017
5,489
5,938
7,314
5,952
0
0
005,9527,3145,9385,4895,0175,5235,20353,84753,20052,67341,57134,89332,45527,00018,92818,85114,0079,3593,095059,39731,4220000000000000000000000000000000000000000000000000000
       Accounts payable 
0
206
708
708
2,332
2,241
729
729
458
458
1,716
1,716
1,429
1,429
1,543
1,543
1,042
1,042
1,496
1,496
1,072
1,072
7,348
7,348
3,038
3,038
7,630
7,630
11,573
11,573
13,217
13,217
20,780
20,780
0
13,885
20,723
20,723
16,863
21,358
0
28,242
23,558
23,980
23,383
27,155
28,119
26,259
26,169
21,805
20,323
18,121
20,475
18,921
19,292
25,120
18,551
13,060
12,740
19,241
19,478
24,972
27,602
28,610
24,275
19,598
16,263
20,919
23,079
23,079
17,663
22,992
20,972
20,145
10,760
10,760
10,76010,76020,14520,97222,99217,66323,07923,07920,91916,26319,59824,27528,61027,60224,97219,47819,24112,74013,06018,55125,12019,29218,92120,47518,12120,32321,80526,16926,25928,11927,15523,38323,98023,55828,242021,35816,86320,72320,72313,885020,78020,78013,21713,21711,57311,5737,6307,6303,0383,0387,3487,3481,0721,0721,4961,4961,0421,0421,5431,5431,4291,4291,7161,7164584587297292,2412,3327087082060
       Other Current Liabilities 
3,824
1,997
1,000
1,000
2,150
2,179
0
0
240
240
0
0
144
144
0
0
143
143
0
0
509
509
21,910
21,910
27,757
27,757
28,867
28,867
32,922
4,712
20,692
2,422
29,808
13,632
0
28,950
21,952
6,024
21,068
9,071
0
6,720
16,842
2,695
2,874
2,260
3,202
2,840
3,492
14,865
2,447
3,470
4,386
5,082
8,101
8,689
25,951
31,271
57,352
57,716
57,211
65,171
60,095
20,859
21,598
18,710
19,649
28,343
20,091
20,091
2,586
3,933
4,450
5,426
12,073
12,073
12,07312,0735,4264,4503,9332,58620,09120,09128,34319,64918,71021,59820,85960,09565,17157,21157,71657,35231,27125,9518,6898,1015,0824,3863,4702,44714,8653,4922,8403,2022,2602,8742,69516,8426,72009,07121,0686,02421,95228,950013,63229,8082,42220,6924,71232,92228,86728,86727,75727,75721,91021,910509509001431430014414400240240002,1792,1501,0001,0001,9973,824
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
197,113
0
192,982
0
202,858
0
303,730
0
284,921
0
326,242
0
345,535
0
256,520
249,946
126,442
124,251
121,264
109,098
102,250
89,538
67,615
96,863
122,432
133,797
129,967
130,261
126,732
108,547
112,476
101,288
94,133
86,369
77,539
66,649
69,047
69,174
110,976
113,725
113,725
112,887
113,482
114,356
125,595
130,187
130,187
130,187130,187125,595114,356113,482112,887113,725113,725110,97669,17469,04766,64977,53986,36994,133101,288112,476108,547126,732130,261129,967133,797122,43296,86367,61589,538102,250109,098121,264124,251126,442249,946256,5200345,5350326,2420284,9210303,7300202,8580192,9820197,11300000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,218
67,279
68,797
72,679
65,713
63,340
63,146
55,598
46,326
49,530
50,209
94,484
96,697
98,702
100,534
101,984
103,689
106,483
0
0
00106,483103,689101,984100,53498,70296,69794,48450,20949,53046,32655,59863,14663,34065,71372,67968,79767,27970,21800000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
15
75,069
75,069
88,794
88,794
78,394
78,394
64,202
64,202
62,541
62,541
56,820
56,820
0
136,779
126,336
126,336
117,082
117,923
0
115,985
110,254
107,133
104,749
63,749
64,663
64,802
55,729
52,957
43,143
43,703
44,341
63,035
72,638
69,580
60,043
59,453
39,750
39,797
35,575
30,793
23,223
21,941
20,323
19,517
18,965
16,492
15,679
15,023
12,353
11,498
0
19,112
0
0
0019,112011,49812,35315,02315,67916,49218,96519,51720,32321,94123,22330,79335,57539,79739,75059,45360,04369,58072,63863,03544,34143,70343,14352,95755,72964,80264,66363,749104,749107,133110,254115,9850117,923117,082126,336126,336136,779056,82056,82062,54162,54164,20264,20278,39478,39488,79488,79475,06975,069151500000000000000000000
> Total Stockholder Equity
20,308
19,151
16,530
16,530
11,965
11,965
24,910
24,910
20,539
20,539
29,452
29,452
26,216
26,216
18,774
18,774
25,790
25,790
23,092
23,092
37,919
37,919
416,337
416,337
515,844
515,844
496,026
496,026
478,848
478,848
453,522
453,522
630,266
630,266
630,266
637,756
571,718
571,718
512,526
584,874
478,601
609,359
452,826
492,754
478,935
528,161
509,872
510,517
540,401
516,766
559,590
575,605
556,135
546,008
527,599
524,557
500,942
481,052
475,147
500,804
487,813
549,326
538,506
518,731
600,930
581,397
559,746
535,509
497,044
497,044
522,807
500,002
482,168
501,838
508,731
508,731
508,731508,731501,838482,168500,002522,807497,044497,044535,509559,746581,397600,930518,731538,506549,326487,813500,804475,147481,052500,942524,557527,599546,008556,135575,605559,590516,766540,401510,517509,872528,161478,935492,754452,826609,359478,601584,874512,526571,718571,718637,756630,266630,266630,266453,522453,522478,848478,848496,026496,026515,844515,844416,337416,33737,91937,91923,09223,09225,79025,79018,77418,77426,21626,21629,45229,45220,53920,53924,91024,91011,96511,96516,53016,53019,15120,308
   Common Stock
22,662
20,668
20,668
20,668
20,668
20,668
37,378
37,378
37,422
37,422
51,019
51,019
51,019
51,019
52,004
52,004
62,460
62,460
64,787
64,787
87,949
87,949
366,853
366,853
477,115
477,115
481,593
481,593
485,004
485,004
487,919
487,919
654,458
654,458
0
675,483
677,087
677,087
592,397
678,227
0
737,260
709,593
768,832
770,301
770,272
770,289
791,788
830,130
830,425
878,669
878,989
879,482
889,481
889,980
909,235
910,405
910,405
910,942
959,635
960,447
1,051,450
1,063,005
1,065,539
1,162,188
1,163,153
1,163,492
1,163,586
1,165,309
1,165,309
1,207,734
1,207,714
1,207,500
1,249,123
1,286,229
1,286,229
1,286,2291,286,2291,249,1231,207,5001,207,7141,207,7341,165,3091,165,3091,163,5861,163,4921,163,1531,162,1881,065,5391,063,0051,051,450960,447959,635910,942910,405910,405909,235889,980889,481879,482878,989878,669830,425830,130791,788770,289770,272770,301768,832709,593737,2600678,227592,397677,087677,087675,4830654,458654,458487,919487,919485,004485,004481,593481,593477,115477,115366,853366,85387,94987,94964,78764,78762,46062,46052,00452,00451,01951,01951,01951,01937,42237,42237,37837,37820,66820,66820,66820,66820,66822,662
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-658
0
0
0
-1,393
0
0
0
-2,337
0
0
0
-4,539
0
0
0
-5,083
0
0
0
-6,685
0
0
0
-7,516
0
0
0
-7,708
0
0
0
-10,386
0
0
0
65,813
66,468
68,082
70,651
70,651
70,873
72,574
73,554
73,520
75,846
75,846
75,84675,84673,52073,55472,57470,87370,65170,65168,08266,46865,813000-10,386000-7,708000-7,516000-6,685000-5,083000-4,539000-2,337000-1,393000-65800000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
515,670
0
29,553
0
75,028
0
90,959
0
75,753
0
136,250
0
174,791
0
23,367
25,012
31,059
27,468
26,665
27,991
37,928
32,845
34,837
36,011
44,235
37,309
39,617
39,802
48,346
40,507
42,054
43,514
57,020
48,803
52,186
64,251
65,813
66,468
68,082
69,279
70,651
70,873
72,574
-39,448
-428,318
0
0
00-428,318-39,44872,57470,87370,65169,27968,08266,46865,81364,25152,18648,80357,02043,51442,05440,50748,34639,80239,61737,30944,23536,01134,83732,84537,92827,99126,66527,46831,05925,01223,3670174,7910136,250075,753090,959075,028029,5530515,67000000000000000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue7,501
Cost of Revenue-54,922
Gross Profit-47,421-47,421
 
Operating Income (+$)
Gross Profit-47,421
Operating Expense-76,790
Operating Income-69,289-124,211
 
Operating Expense (+$)
Research Development27,189
Selling General Administrative25,374
Selling And Marketing Expenses27,733
Operating Expense76,79080,296
 
Net Interest Income (+$)
Interest Income18,776
Interest Expense-19,444
Other Finance Cost-18,623
Net Interest Income-19,291
 
Pretax Income (+$)
Operating Income-69,289
Net Interest Income-19,291
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-82,101-75,768
EBIT - interestExpense = -88,580
-82,101
-62,445
Interest Expense19,444
Earnings Before Interest and Taxes (EBIT)-69,136-62,657
Earnings Before Interest and Taxes (EBITDA)-65,029
 
After tax Income (+$)
Income Before Tax-82,101
Tax Provision--212
Net Income From Continuing Ops-81,889-81,889
Net Income-81,889
Net Income Applicable To Common Shares-81,889
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses76,790
Total Other Income/Expenses Net6,47919,291
 

Technical Analysis of Mesoblast
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mesoblast. The general trend of Mesoblast is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mesoblast's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mesoblast Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.96232416349624 < 0.9624 < 0.975.

The bearish price targets are: 0.71 > 0.49304077669903 > 0.42666666666667.

Tweet this
Mesoblast Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mesoblast Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mesoblast Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mesoblast Ltd.

Mesoblast Ltd Daily Moving Average Convergence/Divergence (MACD) ChartMesoblast Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mesoblast Ltd. The current adx is .

Mesoblast Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mesoblast Ltd.

Mesoblast Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mesoblast Ltd.

Mesoblast Ltd Daily Relative Strength Index (RSI) ChartMesoblast Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mesoblast Ltd.

Mesoblast Ltd Daily Stochastic Oscillator ChartMesoblast Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mesoblast Ltd.

Mesoblast Ltd Daily Commodity Channel Index (CCI) ChartMesoblast Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mesoblast Ltd.

Mesoblast Ltd Daily Chande Momentum Oscillator (CMO) ChartMesoblast Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mesoblast Ltd.

Mesoblast Ltd Daily Williams %R ChartMesoblast Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mesoblast Ltd.

Mesoblast Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mesoblast Ltd.

Mesoblast Ltd Daily Average True Range (ATR) ChartMesoblast Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mesoblast Ltd.

Mesoblast Ltd Daily On-Balance Volume (OBV) ChartMesoblast Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mesoblast Ltd.

Mesoblast Ltd Daily Money Flow Index (MFI) ChartMesoblast Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mesoblast Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Mesoblast Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mesoblast Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.925
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Mesoblast with someone you think should read this too:
  • Are you bullish or bearish on Mesoblast? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mesoblast? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mesoblast Ltd

I send you an email if I find something interesting about Mesoblast Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Mesoblast Ltd.

Receive notifications about Mesoblast Ltd in your mailbox!